AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04045821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dilation and curettage
Description: all participants will undergo routine D\&C procedure
Study NCT01076283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen 10mg t.i.d.
Study NCT01076283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyproheptadine
Description: 'active' placebo
Study NCT03852966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-i/ADHD
Description: Cognitive Behavioral Therapy for insomnia adjusted for patients with ADHD
Study NCT03044522 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Opioid Education
Study NCT02385019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease
Description: Regulatory T cells selected by a sequential 2 step procedure:~1. - Negative selection of CD8 and CD19 cells~2. - Positive selection of CD25 cells
Study NCT01412190 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Vital Light
Description: Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.
Study NCT01412190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: One side of face, one hand and one side of the décolletage is left untreated as a control.
Study NCT01852331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGD granules
Description: The preparation of Peony-Glycyrrhiza Decoction (PGD) granules is in compliance with Pharmacopoeia of the People's Republic of China and Good Manufacturing Practice (GMP). Briefly, sliced, broiled Paeoniae Alba Radix and Glycyrrhizae Radix in a ratio of 1:1 in weight will be immersed and boiled in an 8-fold volume of distilled water for 2.5 hours. This process will be repeated twice. The extract solution will be pooled and concentrated into granule form. Weight of the resulting granules contained in two 9g-sachet packs (to be taken in one day) is equivalent to 45 g raw herbal materials which are supplied for one day.
Study NCT01852331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo granules are prepared to be identical to PGD granules in smell, taste and color.
Study NCT04191109 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study in which the amount of therapy performed during the rehabilitation program will be registered.Data regarding feasibility and safety of the program will be also recorded. Indeed, functional, cognitive and quality of life outcomes will be assessed.
Study NCT01069575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides
Description: Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
Study NCT04313569 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic menisctomy
Description: Arthroscopic medial menisctomy
Study NCT03821337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Trans Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that is able to alter cortical excitability and is FDA-approved to treat Major Depressive Disorder. Magnetic fields pass unimpeded through the scalp, skull and meninges, and can directly excite cortical areas.
Study NCT03821337 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TMS
Description: Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of TMS, combined with a TENS device which produces a small electric shock mimicking the feeling of real rTMS. This type of sham has been demonstrated to be indistinguishable from real rTMS, has been well tolerated (George et al., 2010; George et al., 2014) and successfully used in other clinical trials (Borckardt et al., 2008; Arana et al., 2008). During each session of rTMS the investigators will present a series of opioid related images, including those utilized in previous studies (Garland et al., 2015; Garland \& Howard, 2014).
Study NCT03312608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Navigated transcranial magnetic stimulation
Study NCT01235572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard follow-up care
Description: Undergo early discharge and standard outpatient care
Study NCT01235572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical chart review
Description: Undergo early discharge and standard outpatient care
Study NCT01235572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01954368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a planned weight-based volume of intranasal placebo (normal saline solution).~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse.
Study NCT01954368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a weight-based volume (corresponding to 0,4 mcg/kg) of intranasal sufentanil.~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse.
Study NCT04586413 — intervention group
Intervention type: OTHER
Intervention: No intervention - quality of life measure
Description: Participants will be part of the creation of a Post-COVID-19 quality of life measure if involved in Phase One. In Phase Two participants will complete this post-COVID-19 quality of life measure monthly for 12 months
Study NCT03561337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PROTEIN-CARBOHYDRATE
Description: PRO before and PRO-CHO after training
Study NCT03561337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CARBOHDYRATE
Description: CHO before and after training
Study NCT02699606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive 8 mg of erdafitinib, once daily with option to up-titrate to 9 mg.
Study NCT03891667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disulfiram
Description: Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.
Study NCT03891667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.
Study NCT03095274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab, 1500 mg Q4W for 12 months.
Study NCT03095274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 75 mg Q4W for up to 4 doses/cycles.
Study NCT03352258 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose radiotherapy
Description: 10 Gy in 5 fractions of 2 Gy on 5 consecutive days
Study NCT03813407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level
Description: Sodium Zirconium Cyclosilicate (SZC) Dose: Paediatric dose based on body weight equivalent to an adult 2.5 g
Study NCT03813407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)
Description: Sodium Zirconium Cyclosilicate (SZC)Paediatric dose based on body weight equivalent to an adult 5 g
Study NCT03813407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)
Description: Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 10 g
Study NCT03813407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)
Description: Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 15 g
Study NCT03813407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase
Description: A 28-day period during which SZC is administered orally once daily (QD) to maintain normokalaemia. A dose titration regimen starting with QD administration of the dose of SZC the participants received TID in the CP will be studied in the MP and continued in the LTMP. The maximum dose that can be used is the calculated body weight equivalent to the 15 g adult dose
Study NCT00606346 — intervention group
Intervention type: BIOLOGICAL
Intervention: Anti TNF therapy including infliximab
Description: Treatments will be prescribed according to investigator judgement.
Study NCT00606346 — intervention group
Intervention type: DRUG
Intervention: No Biologics
Description: Treatments will be prescribed according to investigator judgement.
Study NCT04660994 — intervention group
Intervention type: OTHER
Intervention: Educational game
Description: The Yapouni educational game is based on a hot air balloon that will fly according to the number of hours the child has slept with his/her CPAP / NIV. Thus, the longer the child sleeps with his/her CPAP / NIV, the farther and higher his/her hot air balloon will fly in the sky. The game includes wild cards and rewards that are worked out with the child and his/her parents for an optimal individualized adaptation.~The game is explained at Necker Hospital during the therapy education for CPAP/NIV and used at home for 1 month.
Study NCT03804424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-LLP2A
Description: -64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
Study NCT03804424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: -All PET imaging will be performed as PET/MR or PET/CT
Study NCT03570632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants randomized to metformin will receive metformin in addition to standard treatment of diabetes during pregnancy
Study NCT03804424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples for serum stability
Description: -3 venous samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (2 mL each) will be obtained at the following time points: Cohort 1: prior to injection, at completion of dynamic scanning in those who undergo dynamic imaging and at completion of one of the body imaging time points. In those who do not undergo dynamic imaging, prior to injection, and after completing body imaging at 2 of the 3 time points. Cohort 2: subjects will have samples drawn prior to injection, at completion of dynamic scanning, and at completion of body imaging.
Study NCT03804424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples for metabolite analysis
Description: -Typically, 2 blood samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (preferably 1 within the first 5 min and 1 at the completion of the first hour of imaging) will be obtained.
Study NCT03804424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urine sample
Description: -Cohort 1 only
Study NCT03804424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: -Cohort 2 only and only if there hasn't been a recent biopsy of disease
Study NCT03804424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: -A standard 12-lead ECG will be obtained on all subjects at baseline (within 30 mins prior to injection of 64Cu-LLP2A), and at least 60 minutes post injection or prior to study discharge
Study NCT03804424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: -All PET imaging will be performed as PET/MR or PET/CT
Study NCT03681990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep
Description: Apply topically to intact skin
Study NCT05861492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue Differential Diagnosis Aid
Description: The Fatigue Differential Diagnosis Aid is a systematic questionnaire covering the symptoms and signs of fatigue and the collateral clinical data trying to facilitate the diagnostic process in the care of patient with symptoms of fatigue.
Study NCT04252859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluoroestradiol (FES) PET/CT
Description: \[18F\]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)
Study NCT05729945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home visiting
Description: The intervention is a three year program that serves families and their first born children through home visiting using paraprofessionals to deliver a hybrid curriculum using the Partners for a Healthy Baby curriculum developed by Florida State University in January 2015.
Study NCT04577833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally.
Study NCT04577833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate (AA)
Description: Abiraterone Acetate will be administered orally.
Study NCT04577833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally.
Study NCT02276885 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PBI Radiotherapy 6 Gy
Description: Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 6 Gy x 5, over 5 consecutive days
Study NCT02276885 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PBI Radiotherapy 8 Gy
Description: Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 8 Gy x 3, over 5 days, every other day
Study NCT03754205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microablative Fractional CO2 laser
Description: 3 therapies intravaginally administered will be applied at monthly intervals
Study NCT03754205 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Microablative Fractional CO2 laser
Description: 3 therapies intravaginally administered will be applied at monthly intervals
Study NCT00793156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalfurafine HCl 2.5 µg
Description: Daily dose of 2.5 µg
Study NCT00793156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalfurafine HCl 5.0 µg
Description: Daily dose of 5.0 µg
Study NCT00793156 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily dose
Study NCT02889666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Procedure: Preoperative chemotherapy using Cisplatin (60mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
Study NCT02889666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Procedure: Preoperative chemotherapy using Carboplatin (400mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
Study NCT02889666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Procedure: Preoperative chemotherapy using Docetaxel (120mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
Study NCT02889666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Carboplatin
Description: Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
Study NCT02889666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin
Description: Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Cisplatin (60mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
Study NCT02889666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/Oxaliplatin
Description: Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Oxaliplatin (200mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
Study NCT02889666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/Carboplatin
Description: Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
Study NCT02889666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Regular placebo in replacement of agent-specific chemotherapy was supplied to these patients.
Study NCT02727686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Load (WL) Post-Operative Day 1
Description: Patient will have normonatremic 0600 hr sodium level (Serum Sodium = 135 - 145 mmol/L), ability to safely take water by mouth, and cleared to continue by treating surgeon. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Vasopressin level will be determined. Patient will have 30 minutes to consume WL, or will be excluded. Included patients will have data collected as follows: 1 hour - serum sodium, urine output; 2 hour - serum sodium, urine output, vasopressin level; 6 hours - serum sodium, urine output.
Study NCT04041050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral
Study NCT04041050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Tablet; Oral
Study NCT04041050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Capsule; Oral
Study NCT04130139 — intervention group
Intervention type: OTHER
Intervention: oocyte pick up simulator
Description: oocyte pick up simulation
Study NCT02048748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weight and blood pressure device
Description: Weight and blood pressure device integrated in a home telemonitoring kit. The weight scale is Withings The Smart Bodyscale. The blood pressure device is MEDISANA iHealth BP3.
Study NCT02048748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home telemonitoring device
Description: An iPad 2 WiFi 16GB (Model A1395) tablet integrating the telemonitoring kit.
Study NCT04096612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orbital decompression combined with MPT
Description: Orbital decompression combined with MPT
Study NCT02320747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Study NCT01410942 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules by mouth twice daily.
Study NCT01410942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Starting dose 5 mg by mouth twice daily.
Study NCT01410942 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counseling Sessions
Description: 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each.
Study NCT01410942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling Sessions
Description: 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each.
Study NCT01410942 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Exercise
Description: Participants in placebo/sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
Study NCT01410942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Exercise
Description: Participants in placebo/sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
Study NCT01410942 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standardized Exercise Intervention Program
Description: Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.